All entries for: PharmassetX

PharmassetX raised $0.15 million to advance galenexib, an FDA-designated orphan drug for the treatment of pouchitis, a rare chronic inflammatory disease.

PharmassetX raised $0.05 million to develop PSX-514, a novel small-molecule drug and an FDA-designated orphan therapy for pouchitis, aimed at addressing a significant unmet need in the treatment of chronic inflammatory diseases.